BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19263296)

  • 1. Update on genetic and molecular markers associated with myelodysplastic syndromes.
    Valent P; Wieser R
    Leuk Lymphoma; 2009 Mar; 50(3):341-8. PubMed ID: 19263296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
    Harada H; Harada Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
    Harada H; Harada Y; Kimura A
    Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
    Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
    Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic aspects of myelodysplastic syndromes.
    Bartram CR
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):557-70. PubMed ID: 1613006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis of MDS: morphology, chromosome abnormalities and genetic mutations].
    Hata T
    Rinsho Ketsueki; 2015 Oct; 56(10):1978-84. PubMed ID: 26458436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.
    Wall M
    Methods Mol Biol; 2017; 1541():209-222. PubMed ID: 27910026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Nardi V; Hasserjian RP
    Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
    Greenberg PL
    J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
    Guo J; Chang CK; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on cytogenetic and molecular changes in myelodysplastic syndromes.
    Schlegelberger B; Göhring G; Thol F; Heuser M
    Leuk Lymphoma; 2012 Apr; 53(4):525-36. PubMed ID: 21877899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular genetics in myelodysplastic syndromes.
    Haferlach T
    Leuk Res; 2012 Dec; 36(12):1459-62. PubMed ID: 22986016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.